Abstract

Aims: Histidine triad nucleotide-binding protein 1 (HINT1) exhibits proapoptotic and tumor-suppressive activity. HINT1 binds to transcription factors such as teneurin1 and to the regulator of G protein signaling 17 (RGS) (Z2) protein, which incorporates the small ubiquitin-like modifier (SUMO), and is implicated in several types of cancer. HINT1 interacts with proteins such as PKCγ and Raf-1 through zinc ions provided by the cysteine-rich domain of RGSZ2 and the coupled neural nitric oxide synthase (nNOS). Recently, a series of HINT1 mutants have been reported to cause human autosomal recessive axonal neuropathy with neuromyotonia (ARAN-NM). However, the specific alteration in the function of HINT1 induced by these mutants remains to be elucidated. Because sumoylation modifies protein association and transcriptional regulation, we investigated whether HINT1 exhibits zinc- and redox-regulated sumoylase activity, which may be altered in those mutants.Results: HINT1 exhibits cysteine protease activity to remove SUMO from a variety of signaling proteins. HINT1 sumoylase activity is blocked by zinc, and it is released by nitric oxide or calcium-activated calmodulin (CaM). HINT1 contains a SUMO-interacting motif (110–116 HIHLHVL) and the catalytic triad Cys84-Asp87-His114 in the C-terminal region. Thus, zinc probably provided by the RGSZ2–nNOS complex may bind to Cys84 to block HINT1 isopeptidase activity.Innovation: To date, HINT1 is the only sumoylase that is regulated by two alternate pathways, redox- and calcium-activated CaM.Conclusion: The 15 human HINT1 mutants reported to cause ARAN-NM exhibited altered sumoylase activity, which may contribute to the onset of this human motor disease.

Highlights

  • The histidine triad nucleotide-binding protein 1 (HINT1) is a zinc-binding protein of *14 kDa that is highly conserved in phylogeny

  • As Histidine triad nucleotide-binding protein 1 (HINT1) interactions with signaling proteins and nucleotide hydrolase activity can be regulated by zinc [43, 53], we studied whether HINT1 might regulate small ubiquitin-like modifier (SUMO) posttranslational modification of interacting proteins by zinc and redox mechanisms and whether such a novel function was found to be altered in the autosomal recessive axonal neuropathy with neuromyotonia (ARAN-NM)-related mutants

  • Our study shows that HINT1 cleaves sumoylated substrates, such as regulator of G protein signaling 17 (RGS)-Rz proteins, intracellular domain (ICD) teneurin1, and Ran GTPase activating protein 1 (RanGAP1), and that this activity is inhibited by zinc and promoted by nitric oxide (NO) or calciumactivated calmodulin (CaM)

Read more

Summary

Introduction

The histidine triad nucleotide-binding protein 1 (HINT1) is a zinc-binding protein of *14 kDa that is highly conserved in phylogeny. HINT1 is widely expressed in the central nervous system (CNS) and other tissues [27, 32], and at the cellular level, this protein is present in the plasma membrane, nucleus, and cytoplasm. HINT1 was initially described as a protein kinase C (PKC)-inhibiting protein [39], and, conventional PKCc and PKCa establish nitric oxide (NO) and zinc-dependent inhibitory associations with HINT1 [43, 44]. Crystallization studies indicated that HINT1 exists as a homodimer with the protomers interacting through their Cterminal sequences [26, 35], and its amino acid sequence revealed that it belongs to the histidine triad (HIT) family with HINT2 and HINT3 as its closest paralogs.

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.